Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

U.S. Marshals Seize Drug Products Manufactured By Caraco Pharmaceutical Laboratories Ltd. FDA Acts To Prevent Repeated Drug Quality Problems
U.S. Marshals, at the request of the Food and Drug Administration, today seized drug products manufactured by Caraco Pharmaceutical Laboratories Ltd. (Caraco), at the company"s Michigan facilities in Detroit, Farmington Hills, and Wixom. The seizure also includes ingredients held at these same facilities. "The FDA is committed to taking enforcement action against firms that do not manufacture drugs in accordance with our good manufacturing practice requirements," said Janet Woodcock, M.D., director of the FDA"s Center for Drug Evaluation and Research. "Compliance with these standards prevents harm to the public."

Brits Are Europe's Angriest People, Says New Poll But All We Do Is Bite Our Lips, Says British Association Of Anger Management, United Kingdom
A poll commissioned by comedy channel Gold and to be revealed shows that we Britons are the angriest people in Europe, losing our cool on average four times a day and topping even the Italians and French. And what do we believe makes us most angry? Queue jumpers.
News of the day
Exelixis Reports Encouraging Phase 1 Data To Be Presented At ASCO For XL228, A Multi-Targeted Inhibitor Of Key Cancer Signaling Kinases
Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing Phase 1 dose-escalation trial of XL228 in patients with advanced malignancies. XL228 is a small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R), SRC, Aurora kinases, and fibroblast growth factor receptor types 1, 2, and 3 (FGFR1-3), which are associated with cancer cell proliferation, survival, and metastasis. The compound also inhibits BCR-ABL, including the T315I mutant form which is resistant to currently approved inhibitors. David Smith, MD, Professor of Medicine at the University of Michigan, an investigator on the Phase 1 trial, will present the data in an oral session (Abstract #3512) beginning at 4:15 p.m. local time on Saturday, May 30, 2009, at the American Society of Clinical Oncology Annual Meeting, which is being held May 29-June 2 in Orlando.
Diagnostics

House Passes Spending Bill; Amendment To Block Removal Of Needle Exchange Funding Ban Defeated

The House on Friday passed a $730.5 billion bill (HR 3293) "to fund health, education and labor programs in fiscal 2010 after narrowly defeating an attempt to strip language that would lift the ban on federal needle exchange programs," in the U.S., CQ Today reports (Wolfe, 7/24). Lawmakers voted 211-218 to reject an amendment by Mark Souder (R-Ind.) that sought to keep the ban in place, the AP/Lewiston Sun Journal reports (Taylor, 7/25). The bill that passed includes a restriction against using federal funds for needle exchanges within 1,000 feet of day care centers, schools, parks, playgrounds, pools and youth centers, the Washington Post reports. Ronald Johnson, deputy executive director of the Washington, D.C.,-based advocacy group AIDS Action, said, "This is the first time in over 20 years that we are on the verge of recognition by the federal government of the proven cost-effectiveness and impact of syringe exchange as a very important tool for prevention of HIV infection and viral hepatitis," adding, "Allowing the local community to use federal funds is very critical to stopping these epidemics" (Fears, 7/25). The bill also drops funding for abstinence-only sex education and "would provide $114 million for a new teenage pregnancy prevention initiative," the Sun Journal article states (7/25). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009